Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEAMERICAN:ARMPNASDAQ:AYLANASDAQ:BCLIOTCMKTS:BCYPNASDAQ:FENC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARMPArmata Pharmaceuticals$2.53+1.2%$0.00$1.07▼$5.26$91.46M0.8517,066 shs4,325 shsAYLAAyala Pharmaceuticals$0.48$0.36▼$7.31$7.46M1.9876,300 shs137,700 shsBCLIBrainstorm Cell Therapeutics$0.53-2.4%$0.47$0.13▼$3.34$36.36M0.28977,610 shs227,981 shsBCYPBig Cypress Acquisition$8.44-19.2%$8.44$8.21▼$12.90$124.84MN/A160,982 shs15.34 million shsFENCFennec Pharmaceuticals$9.24+1.9%$10.05$6.30▼$11.92$250.40M0.38114,753 shs97,738 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARMPArmata Pharmaceuticals0.00%0.00%0.00%0.00%0.00%AYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BCLIBrainstorm Cell Therapeutics+3.81%+0.78%-16.79%+75.69%-80.40%BCYPBig Cypress Acquisition0.00%0.00%0.00%0.00%0.00%FENCFennec Pharmaceuticals-1.84%-6.49%-17.55%-12.96%+14.09%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARMPArmata Pharmaceuticals2.4339 of 5 stars3.55.00.00.00.61.70.6AYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics0.4422 of 5 stars0.03.00.04.70.60.00.6BCYPBig Cypress AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals2.5191 of 5 stars3.50.00.00.02.42.51.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARMPArmata Pharmaceuticals3.00Buy$7.00176.68% UpsideAYLAAyala PharmaceuticalsN/AN/AN/AN/ABCLIBrainstorm Cell Therapeutics2.00HoldN/AN/ABCYPBig Cypress AcquisitionN/AN/AN/AN/AFENCFennec Pharmaceuticals3.00Buy$17.3387.59% UpsideCurrent Analyst RatingsLatest BCYP, AYLA, BCLI, ARMP, and FENC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/22/2024ARMPArmata PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARMPArmata Pharmaceuticals$4.53M20.19N/AN/A($0.89) per share-2.84AYLAAyala Pharmaceuticals$3.51M0.00N/AN/A$2.45 per share0.00BCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/ABCYPBig Cypress AcquisitionN/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals$21.25M11.78N/AN/A($0.43) per share-21.49Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARMPArmata Pharmaceuticals-$69.04M-$1.98N/AN/AN/A-1,524.51%-280.95%-52.61%5/9/2024 (Estimated)AYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ABCLIBrainstorm Cell Therapeutics-$17.19M-$0.41N/AN/AN/AN/AN/A-376.40%5/20/2024 (Estimated)BCYPBig Cypress Acquisition-$10KN/A0.00N/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.20N/A-75.50%N/A-73.64%5/9/2024 (Estimated)Latest BCYP, AYLA, BCLI, ARMP, and FENC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023BCLIBrainstorm Cell Therapeutics-$0.15-$0.11+$0.04-$0.11N/AN/A3/21/2024Q4 2023ARMPArmata PharmaceuticalsN/A-$0.55-$0.55-$0.55$0.68 million$1.53 million3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARMPArmata PharmaceuticalsN/AN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ABCYPBig Cypress AcquisitionN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARMPArmata PharmaceuticalsN/A1.161.16AYLAAyala PharmaceuticalsN/A2.282.28BCLIBrainstorm Cell TherapeuticsN/A0.240.24BCYPBig Cypress AcquisitionN/A6.136.13FENCFennec PharmaceuticalsN/A3.563.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARMPArmata Pharmaceuticals3.57%AYLAAyala Pharmaceuticals22.10%BCLIBrainstorm Cell Therapeutics14.33%BCYPBig Cypress Acquisition60.21%FENCFennec Pharmaceuticals55.51%Insider OwnershipCompanyInsider OwnershipARMPArmata Pharmaceuticals85.50%AYLAAyala Pharmaceuticals3.60%BCLIBrainstorm Cell Therapeutics5.45%BCYPBig Cypress AcquisitionN/AFENCFennec Pharmaceuticals11.25%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARMPArmata Pharmaceuticals6636.15 million5.24 millionNot OptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableBCLIBrainstorm Cell Therapeutics2968.34 million64.62 millionOptionableBCYPBig Cypress Acquisition514.79 millionN/ANot OptionableFENCFennec PharmaceuticalsN/A27.10 million24.05 millionOptionableBCYP, AYLA, BCLI, ARMP, and FENC HeadlinesSourceHeadlineAdrian Haigh Sells 22,223 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stockinsidertrades.com - April 23 at 5:00 AMFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,222 Sharesinsidertrades.com - April 23 at 4:22 AMFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $207,118.36 in Stockmarketbeat.com - April 22 at 9:20 PMFennec Pharmaceuticals COO sells shares worth over $536kinvesting.com - April 20 at 11:00 PMAdrian Haigh Sells 22,222 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stockamericanbankingnews.com - April 20 at 5:18 AMFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $220,220.02 in Stockinsidertrades.com - April 19 at 6:53 AMFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $228,886.60 in Stockinsidertrades.com - April 18 at 6:32 AMFennec Pharmaceuticals Inc (NASDAQ:FENC) Short Interest Updateamericanbankingnews.com - April 16 at 1:48 AMThose who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136%finance.yahoo.com - April 9 at 2:14 PMFennec Pharmaceuticals CEO sells shares worth over $950kuk.investing.com - April 7 at 11:51 PMInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells 44,300 Shares of Stockinsidertrades.com - April 6 at 7:31 AMFennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov Sells 44,300 Sharesmarketbeat.com - April 5 at 6:39 PMHC Wainwright Comments on Fennec Pharmaceuticals Inc's Q2 2024 Earnings (NASDAQ:FENC)marketbeat.com - April 5 at 8:22 AMRosty Raykov Sells 40,584 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stockinsidertrades.com - April 5 at 5:10 AMBuy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial Outlookmarkets.businessinsider.com - April 4 at 5:55 PMFennec Pharmaceuticals (NASDAQ:FENC) PT Raised to $18.00 at HC Wainwrightmarketbeat.com - April 4 at 8:30 AMInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells 40,584 Shares of Stockmarketbeat.com - April 3 at 6:43 PMFennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $23,190.58 in Stockinsidertrades.com - March 28 at 8:47 AMChief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC)finance.yahoo.com - March 27 at 7:33 PMFennec Pharmaceuticals Inc (NASDAQ:FENC) CFO Sells $153,725.00 in Stockinsidertrades.com - March 26 at 4:44 AMChief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC)finance.yahoo.com - March 26 at 3:23 AMInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) CFO Sells 13,975 Shares of Stockmarketbeat.com - March 25 at 9:31 PMBuy Rating for Fennec Pharmaceuticals Amidst Strong Pedmark Sales and Market Expansion Potentialmarkets.businessinsider.com - March 22 at 8:46 AMQ4 2023 Fennec Pharmaceuticals Inc Earnings Callfinance.yahoo.com - March 22 at 8:46 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArmata PharmaceuticalsNYSEAMERICAN:ARMPArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.Ayala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Brainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Big Cypress AcquisitionOTCMKTS:BCYPBig Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.